# OnCo record aspirin-cancer-prevention (technology). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/technologies/aspirin-cancer-prevention/>
  a schema:MedicalTherapy ;
  onco:kind "technology" ;
  schema:identifier "aspirin-cancer-prevention" ;
  schema:name "Aspirin for cancer prevention and adjuvant therapy"@en ;
  schema:description "Daily low-dose aspirin lowers bowel cancer risk in people with Lynch syndrome and appears to cut recurrence in bowel cancers with a particular mutation. In healthy older people it caused more harm than good."@en ;
  schema:url <https://onco.cc/technologies/aspirin-cancer-prevention/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Aspirin#Cancer_prevention> ;
  owl:sameAs <http://www.wikidata.org/entity/Q18216> ;
  schema:citation <https://doi.org/10.1056/NEJMoa2504650>, <https://doi.org/10.1016/S0140-6736(20)30366-4>, <https://doi.org/10.1056/NEJMoa1803955>, <https://doi.org/10.1016/s0140-6736(20)30366-4>, <https://www.nice.org.uk/guidance/ng151/chapter/Recommendations>, <https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/bowel-cancer/risk-factors> ;
  onco:status "phase-3" ;
  onco:related <https://onco.cc/terms/lynch-syndrome/>, <https://onco.cc/ideas/idea-reg-aspirin-pik3ca-implementation/>, <https://onco.cc/ideas/idea-prev-lynch-aspirin-implementation/>, <https://onco.cc/ideas/idea-bio2-platelet-cloak-aspirin-mrd/> ;
  onco:cancers <https://onco.cc/cancers/colorectal/>, <https://onco.cc/cancers/esophageal/>, <https://onco.cc/cancers/gastric/>, <https://onco.cc/cancers/breast-hr-positive/>, <https://onco.cc/cancers/prostate/>, <https://onco.cc/cancers/lynch-associated-colorectal-cancer/> ;
  onco:sections <https://onco.cc/fronts/nutrition-lifestyle/>, <https://onco.cc/fronts/prevention/> ;
  onco:technologies <https://onco.cc/technologies/chemoprevention/>, <https://onco.cc/technologies/drug-repurposing/> ;
  onco:pathways <https://onco.cc/pathways/pi3k-akt-mtor/> ;
  onco:terms <https://onco.cc/terms/germline-vs-somatic/>, <https://onco.cc/terms/lynch-syndrome/> ;
  onco:trials <https://onco.cc/trials/alascca/>, <https://onco.cc/trials/add-aspirin/>, <https://onco.cc/trials/aspree/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-generic-repurposing/>, <https://onco.cc/bottlenecks/b-funding-allocation/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-mcneil-n-engl-j-med/> .